Updated features associated with type 1 gastric carcinoids patients: a single-center study

References

• Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumours. In collaboration with 9 pathologists from 4 countries. Berlin, New York: Springer; 1999.
   Google Scholar
• Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuorendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104:994–1006.
   PubMed Web of Science ®Google Scholar
• Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012;95:74–87.
   PubMed Web of Science ®Google Scholar
• Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours. IARC press; 2010;3.
   Google Scholar
• Solcia E, Fiocca R, Villani L, Gianatti A, Cornaggia M, Chiaravalli A, et al. Morphology and pathogenesis of endocrine hyperplasias, precarcinoids lesions, and carcinoids arising in chronic atrophic gastritis. Scand J Gastroenterol Suppl 1991;180:146–59.
   PubMedGoogle Scholar
• Solcia E, Rindi G, Paolotti D, Luinetti O, Klersy C, Zangrandi A, et al. Natural history, clinicopathologic classification and prognosis of gastric ECL cell tumours. Yale J Biol Med 1998;71:285–90.
   PubMed Web of Science ®Google Scholar
• Shaib YH, Rugge M, Graham DY, Genta RM. Management of gastric polyps: an endoscopy-based approach. Clin Gastroenteorl Hepatol 2013;11:1374–84.
   PubMed Web of Science ®Google Scholar
• Bordi C, D’Adda T, Azzoni C, Ferraro G. Pathogenesis of ECL cell tumors in humans. Yale J Biol Med 1998;71:273–84.
   PubMed Web of Science ®Google Scholar
• Dockray GJ, Varro A, Dimaline R, Wang T. The gastrins: their production and biological activities. Annu Rev Physiol 2001;63:119–39.
   PubMed Web of Science ®Google Scholar
• Bordi C, D’Adda T, Azzoni C, Pilato FP, Caruana P. Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol 1995;19:S8–19.
   PubMed Web of Science ®Google Scholar
• Borch K, Ahren B, Ahlman H, Falkner S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005;242:64–73.
   PubMed Web of Science ®Google Scholar
• Hosokawa O, Kaizaki Y, Hattori M, Douden K, Hayashi H, Morishita M, et al. Long-term follow-up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer 2005;8:42–6.
   PubMedGoogle Scholar
• Vannella L, Sbrozzi-Vanni A, Lahner E, Bordi C, Pilozzi E, Corleto VD, et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther 2011;33:1361–9.
   PubMed Web of Science ®Google Scholar
• Burkitt MD, Pritchard DM. Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 2006;24:1305–20.
   PubMed Web of Science ®Google Scholar
• Carmack SW, Genta RM, Schuler CM, Saboorian MH. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol 2009;104:1524–32.
   PubMed Web of Science ®Google Scholar
• Annibale B, Azzoni C, Corleto VD, di Giulio E, Caruana P, D’Ambra G, et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol 2001;13:1449–56.
   PubMed Web of Science ®Google Scholar
• Thomas D, Tsolakis AV, Grozinsky-Glasberg S, Fraenkel M, Alexandraki K, Sougioultzis S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoids tumors: data from a multicenter study. Eur J Endocrinol 2013;168:185–93.
   PubMed Web of Science ®Google Scholar
• Sato Y, Imamura H, Kaizaki Y, Koizumi W, Ishido K, Kurahara K, et al. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig Endosc 2014;26:377–84.
   PubMed Web of Science ®Google Scholar
• Dakin GF, Warnern RRP, Pomp A, Salky B, Inabnet WP. Presentation, treatment and outcome of type 1 gastric carcinoids tumors. J Surg Oncol 2006;93:368–72.
   PubMed Web of Science ®Google Scholar
• Annibale B, Marignani M, Azzoni C, D’Ambra G, Caruana P, D’Adda T, et al. Atrophic body gastritis: distinct features associated with Helicobacter pylori infection. Helicobacter 1997;2:57–64.
   PubMed Web of Science ®Google Scholar
• Lahner E, Norman GL, Severi C, Encabo S, Shums Z, Vannella L, et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol 2009;104:2071–9.
   PubMed Web of Science ®Google Scholar
• Lahner E, Centanni M, Agnello G, Gargano L, Vannella L, Iannoni C, et al. Occurrence and risk factors for autoimmune thyroid disease in patients with atrophic body gastritis. Am J Med 2008;121:136–41.
   PubMed Web of Science ®Google Scholar
• Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1998;41:185–200.
   Web of Science ®Google Scholar
• Vigen RA, Chen D, Syversen U, Stunes K, Hakanson R, Zhao CM. Serum gastrin and gastric enterochromaffin-like cells during estrous cycle, pregnancy and lactation, and in response to estrogen-like agents in rats. J Physiol Pharmacol 2011;62:335–40.
   PubMed Web of Science ®Google Scholar
• Helgadottir H, Metz DC, Yang Y-X, Rhim AD, Bjornsson ES. The effects of long-term therapy with proton-pump inhibitors on meal stimulated gastrin. Dig Liver Dis 2014;46:125–30.
   PubMedGoogle Scholar
• Vannella L, Lahner E, Annibale B. Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal. World J Gastroenterol 2012;18:1279–85.
   PubMed Web of Science ®Google Scholar
• Goddard AF, Badreldin R, Pritchard DM, Walker MM, Warren B. The management of gastric polyps. Gut 2010;59:1270–6.
   PubMed Web of Science ®Google Scholar
• Lash JG, Genta RM. Adherence to the Sydney System guidelines increases the detection of Helicobacter gastritis and intestinal metaplasia in 400738 sets of gastric biopsies. Aliment Pharmacol Ther 2013;38:424–31.
   PubMed Web of Science ®Google Scholar
• Tosetti C, Stanghellini V, Tucci A, Poli L, Salvioli B, Biasco G, et al. Gastric emptying and dyspeptic symptoms in patients with nonautoimmune fundic atrophic gastritis. Dig Dis Sci 2000;45:252–7.
   PubMed Web of Science ®Google Scholar
• Stockbruegger RW. Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol Suppl 1985;111:7–16.
   PubMedGoogle Scholar
• Annibale B, Capurso G, Delle Fave G. The stomach and iron deficiency anaemia: a forgotten link. Dig Liver Dis 2003;35:288–95.
   PubMedGoogle Scholar
• Hershko C, Ronson A, Souroujon M, Maschier I, Heyd J, Patz J. Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood 2006;107:1673–9.
   PubMed Web of Science ®Google Scholar
• Alexandraki KI, Nikolaou A, Thomas D, Syriou V, Korkolopoulou P, Sougioultzis S, et al. Are patients with autoimmune thyroid disease and autoimmune gastritis at risk of gastric neuroendocrine neoplasms type 1? Clin Endocrinol(Oxf) 2014;80:685–90.
   PubMed Web of Science ®Google Scholar
• Lahner E, Spoletini M, Buzzetti R, Corleto VD, Vannella L, Petrone A, et al. HLA-DRB1*03 and DRB1*04 are associated with atrophic gastritis in an Italian population. Dig Liver Dis 2010;42:854–9.
   PubMedGoogle Scholar
• Waldum HL, Sandivk AK, Idle JR. Gastrin is the most important factor in ECL tumorigenesis. Gastroenterology 1998;114:1113–15.
   PubMed Web of Science ®Google Scholar